Fig. 1: Investigator-assessed PFS from start of IRd.
A ITT population (N = 140a). B Stratified by age subgroup. C Stratified by frailty subgroup. IMWG International Myeloma Working Group, IRd ixazomib-lenalidomide-dexamethasone, ITT intent-to-treat, PD progressive disease, PFS progression-free survival. aOne successfully screened patient was not treated. PFS defined as the time from first administration of IRd to the date of the first documentation of PD based on local laboratory results and the investigator’s assessment using modified IMWG response criteria, or death due to any cause, whichever occurred first; data are stratified by (A) ITT population; (B) subgroups aged <75 and ≥75 years and (C) subgroups defined as non-frail and frail.
